Novel classes of antibiotics or more of the same?

被引：398

作者：

Coates, Anthony R. M. ^{[1
]}

Halls, Gerry ^{[2
]}

Hu, Yanmin ^{[1
]}

机构：

[1] St Georges Univ London, Ctr Infect, Dept Clin Sci, London SW17 ORE, England

[2] Med Mkt Serv, Beaconsfield, Bucks, England

来源：

BRITISH JOURNAL OF PHARMACOLOGY | 2011年 / 163卷 / 01期

基金：

英国医学研究理事会;

关键词：

novel antibiotics; bacterial infections; antibiotic resistance; genomics; non-culturable bacteria; bacteriophages; non-multiplying bacteria; multiplying bacteria; STAPHYLOCOCCUS-AUREUS; NATURAL-PRODUCTS; ANTIMICROBIAL RESISTANCE; ANTIBACTERIAL DISCOVERY; BAD BUGS; DRUGS; INFECTIONS; CHALLENGES; FUTURE; DAPTOMYCIN;

D O I：

10.1111/j.1476-5381.2011.01250.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

LINKED ARTICLES This article is part of a themed issue on Respiratory Pharmacology. To view the other articles in this issue visit http://dx.doi.org/10.1111/bph.2011.163.issue-1.

引用

页码：184 / 194

页数：11

共 48 条

[1] The biological cost of mutational antibiotic resistance: any practical conclusions? [J].

Andersson, Dan I. .

CURRENT OPINION IN MICROBIOLOGY, 2006, 9 (05) :461-465

[2]

[Anonymous], 2010, ID PHYS CALL 10 NEW

[3] Type IIA topoisomerase inhibition by a new class of antibacterial agents [J].

Bax, Benjamin D. ;

Chan, Pan F. ;

Eggleston, Drake S. ;

Fosberry, Andrew ;

Gentry, Daniel R. ;

Gorrec, Fabrice ;

Giordano, Ilaria ;

Hann, Michael M. ;

Hennessy, Alan ;

Hibbs, Martin ;

Huang, Jianzhong ;

Jones, Emma ;

Jones, Jo ;

Brown, Kristin Koretke ;

Lewis, Ceri J. ;

May, Earl W. ;

Saunders, Martin R. ;

Singh, Onkar ;

Spitzfaden, Claus E. ;

Shen, Carol ;

Shillings, Anthony ;

Theobald, Andrew J. ;

Wohlkonig, Alexandre ;

Pearson, Neil D. ;

Gwynn, Michael N. .

NATURE, 2010, 466 (7309) :935-U51

[4] Antibiotic resistance - what can we do? [J].

Bax, RP ;

Anderson, R ;

Crew, J ;

Fletcher, P ;

Johnson, T ;

Kaplan, E ;

Knaus, B ;

Kristinsson, K ;

Malek, M ;

Strandberg, L .

NATURE MEDICINE, 1998, 4 (05) :545-546

[5] Robust Salmonella metabolism limits possibilities for new antimicrobials [J].

Becker, D ;

Selbach, M ;

Rollenhagen, C ;

Ballmaier, M ;

Meyer, TF ;

Mann, M ;

Bumann, D .

NATURE, 2006, 440 (7082) :303-307

[6] Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America [J].

Boucher, Helen W. ;

Talbot, George H. ;

Bradley, John S. ;

Edwards, John E., Jr. ;

Gilbert, David ;

Rice, Louis B. ;

Scheld, Michael ;

Spellberg, Brad ;

Bartlett, John .

CLINICAL INFECTIOUS DISEASES, 2009, 48 (01) :1-12

[7] Postgenomic strategies in antibacterial drug discovery [J].

Broetz-Oesterhelt, Heike ;

Sass, Peter .

FUTURE MICROBIOLOGY, 2010, 5 (10) :1553-1579

[8] AMOXICILLIN-CLAVOLANIC ACID - A REVIEW OF ITS ANTIBACTERIAL ACTIVITY, PHARMACOKINETICS AND THERAPEUTIC USE [J].

BROGDEN, RN ;

CARMINE, A ;

HEEL, RC ;

MORLEY, PA ;

SPEIGHT, TM ;

AVERY, GS .

DRUGS, 1981, 22 (05) :337-362

[9] Natural products - The future scaffolds for novel antibiotics? [J].

Butler, MS ;

Buss, AD .

BIOCHEMICAL PHARMACOLOGY, 2006, 71 (07) :919-929

[10] Waves of resistance: Staphylococcus aureus in the antibiotic era [J].

Chambers, Henry F. ;

DeLeo, Frank R. .

NATURE REVIEWS MICROBIOLOGY, 2009, 7 (09) :629-641

← 1 2 3 4 5 →